Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U1 small nuclear 124, pseudogene (RNU1-124P), is classified as a small nuclear RNA (snRNA) pseudogene belonging to the broader RNU1 (U1 snRNA) multigene family[2]. Pseudogenes like RNU1-124P are DNA sequences that resemble functional genes but contain mutations or deletions preventing them from producing fully functional transcripts or proteins[2]. Nevertheless, recent research challenges the notion that all such pseudogenes are entirely nonfunctional: some U1 snRNA pseudogenes are actively transcribed and produce variant snRNAs that are packaged into ribonucleoprotein complexes and may modulate gene expression at the level of mRNA processing[2]. However, there is no evidence that RNU1-124P is a therapeutic target, a protein, a functional enzyme, receptor, transporter, or transcription factor[2]. No drugs are known to interact with RNU1-124P, and it is not used as a biomarker or implicated in any safety or therapeutic concerns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 124, pseudogene (RNU1-124P).